The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease
Open accessAbstract
4,500 mild-moderate AD patients randomized to placebo and 0.5mg/kg i.v.every 13 weeks for 18 months in APOE4 carriers, and randomized to placebo, 0.5, 1.0mg/kg i.v.every 13 weeks for 18 months in APOE4 noncarriers in 4 trials (ClinicalTrials.govidentifiers lNCT00575055, NCT00574132, NCT00676143, NCT00667810).Trials were halted after completion of 2 trials demonstrated a failure to meet primary outcome measures on ADAS-cog and activities of daily living.109 Solanezumab, humanized monoclonal antibody directed at amino acids 16-24 of Ab peptide.Amyloid plaque clearance mediated via peripheral sink mechanism.52 mild-moderate AD patients were randomized to placebo, 100mg every 4 weeks, 100mg weekly, 400mg every 4 weeks, 400mg weekly i.v.solanezumab for 12 weeks.There was a significant dose-dependent increase in Ab42 peptide in CSF.132 2,000 mild-moderate AD patients randomized to placebo and 400mg solanezumab monthly i.v. for 18 months (ClinicalTrials.govidentifiers NCT00905372, NCT00904683).Trials failed to meet their primary outcome measures on ADAS-cog and ADCS-ADL.A secondary analysis of mild AD patients pooled from both trials showed a significant effect on cognition.115 Gammagard, intravenous immunoglobulin.55 mild-moderate AD patients randomized to placebo, 0.2, 0.5, 0.8g/kg/4 weeks, or 0.1, 0.25, 0.4g/kg/2 weeks for 24 weeks.There was no increase in Ab40 peptide in plasma at any dose.129 Trial data currently unpublished.390 mild-moderate AD patients randomized to 0.2g/kg/2 weeks and 0.4g/kg/2 weeks vs placebo for 18 months (ClinicalTrials.govIdentifier NCT00818662).Gammagard failed to reach its coprimary outcomes of ADAS-cog and ADCS-ADL.AD 5 Alzheimer disease; ADAS-cog 5 Alzheimer's Disease Assessment Scale-Cognitive Subscale; ADCS-ADL 5 Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory; b.i.d. 5 twice daily; CDR-SB 5 Clinical Dementia Rating-Sum of Boxes; CSF 5 cerebrospinal fluid; i.v. 5 intravenous; o.d. 5 once per day.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Self-citationImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 1×
“The same purified preparations were also shown to inhibit Ab-mediated toxicity in fetal rat primary hippocampal cells, but the interpretation of direct Ab-mediated toxicity assays is challenging.(9) Other workers also demonstrated an antiaggregatory effect of affinitypurified anti-Ab antibodies on Ab-induced toxicity,…”
BackgroundSelf-citationA presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain
De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., et al. (1999) · Nature · doi:10.1038/19083 · Cited by 2,100
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 1×
“5-month-old PDAPP mice were treated with weekly injections of 3D6 for 6 months, the Ab burden (percentage of a brain section of the frontal cortex that can be immunohistochemically stained for Ab) was reduced by 86%.(96) However, it is unclear whether this regime reduced Ab levels to below those present at the start o…”
Method
Cited by
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Self-citationAlzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Lane, C. A., Hardy, J., & Schott, J. M. (2018) · European Journal of Neurology · doi:10.1111/ene.13439 · Cited by 2,616
Self-citationSala Frigerio, C., Wolfs, L., Fattorelli, N., Thrupp, N., Voytyuk, I., Schmidt, I., Mancuso, R., Chen, W.-T., Woodbury, M. E., Srivastava, G., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.099 · Cited by 926
Self-citationMolecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
“Links between Aβ and tau pathogenesis Unlike mutations in APP and PS1/2 that affect Aβ generation in early onset familial AD [285, 286], mutations in MAPT have not been associated with AD [287, 288], suggesting that tau pathogenesis may occur downstream of Aβ accumulation [289].”
BackgroundAmyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742
“…other agents in Table 1 — tarenflurbil, tramiprosate and gammagard — for which we consider that their proposed primary pharmacology and mechanism of action are not strongly supported by available data, and/or target engagement in humans was never established; for a review of these agents, see 31 .”
Self-citationProtein misfolding in neurodegenerative diseases: Implications and strategies
Sweeney, P., Park, H., Baumann, M., Dunlop, J., Frydman, J., Kopito, R., McCampbell, A., Leblanc, G., Venkateswaran, A., Nurmi, A., et al. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0077-5 · Cited by 675
Kennedy, M. E., Stamford, A. W., Chen, X., Cox, K., Cumming, J. N., Dockendorf, M. F., Egan, M., Ereshefsky, L., Hodgson, R. A., Hyde, L. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9704 · Cited by 428
The amyloid cascade hypothesis: are we poised for success or failure?
Karran, E., & De Strooper, B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13632 · Cited by 402
Self-citationCalcium signaling and molecular mechanisms underlying neurodegenerative diseases
Pchitskaya, E., Popugaeva, E., & Bezprozvanny, I. (2018) · Cell Calcium · doi:10.1016/j.ceca.2017.06.008 · Cited by 349
Pan, R.-Y., Ma, J., Kong, X.-X., Wang, X.-F., Li, S.-S., Qi, X.-L., Yan, Y.-H., Cheng, J., Liu, Q., Jin, W., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau6328 · Cited by 288
The amyloid cascade hypothesis: an updated critical review
Kepp, K. P., Robakis, N. K., Høilund-Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023) · Brain · doi:10.1093/brain/awad159 · Cited by 284
Lessons from a failed γ-secretase Alzheimer trial
De Strooper, B. (2014) · Cell · doi:10.1016/j.cell.2014.10.016 · Cited by 277
Clearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
Zuroff, L., Daley, D., Black, K. L., & Koronyo-Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 275
Poor Translatability of Biomedical Research Using Animals — A Narrative Review
Marshall, L. J., Bailey, J., Cassotta, M., Herrmann, K., & Pistollato, F. (2023) · Alternatives to Laboratory Animals · doi:10.1177/02611929231157756 · Cited by 219
Structural basis of γ-secretase inhibition and modulation by small molecule drugs
Yang, G., Zhou, R., Guo, X., Yan, C., Lei, J., & Shi, Y. (2021) · Cell · doi:10.1016/j.cell.2020.11.049 · Cited by 189
New Approaches for the Treatment of Alzheimer’s Disease
Fish, P. V., Steadman, D., Bayle, E. D., & Whiting, P. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.11.034 · Cited by 189
Cummings, J., Ritter, A., & Zhong, K. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179901 · Cited by 176
Petrov, D., Pedrós, I., Artiach, G., Sureda, F. X., Barroso, E., Pallàs, M., Casadesús, G., Beas-Zarate, C., Carro, E., Ferrer, I., et al. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.004 · Cited by 163
Irreproducibility in Preclinical Biomedical Research: Perceptions, Uncertainties, and Knowledge Gaps
Jarvis, M. F., & Williams, M. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.12.001 · Cited by 129
Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics
Sala Frigerio, C., & De Strooper, B. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014015 · Cited by 116
Genetic risk for alzheimer disease is distinct from genetic risk for amyloid deposition
Leonenko, G., Shoai, M., Bellou, E., Sims, R., Williams, J., Hardy, J., Escott‐Price, V., & Initiative, T. A. D. N. (2019) · Annals of Neurology · doi:10.1002/ana.25530 · Cited by 114
Self-citationMullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.026 · Cited by 98
Ferreira, J. P. S., Albuquerque, H. M. T., Cardoso, S. M., Silva, A. M. S., & Silva, V. L. M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113492 · Cited by 96
Caselli, R. J., Beach, T. G., Knopman, D. S., & Graff-Radford, N. R. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.02.011 · Cited by 81
“984 approach has caused intense reconsideration of current disease models, trial design, and diagnostic and therapeutic approaches.(66) Progress in light of these setbacks has led to a greater understanding of AD’s extended preclinical phases; the development of imaging and biofluid biomarkers for earlier detection an…”
Cavedo, E., Lista, S., Khachaturian, Z., Aisen, P., Amouyel, P., Herholz, K., Jack Jr, C. R., Sperling, R., Cummings, J., Blennow, K., et al. (2014) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2014.32 · Cited by 67
Giuffrida, M. L., Tomasello, M. F., Pandini, G., Caraci, F., Battaglia, G., Busceti, C., Di Pietro, P., Pappalardo, G., Attanasio, F., Chiechio, S., et al. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00297 · Cited by 52
DAPK1: a Novel Pathology and Treatment Target for Alzheimer’s Disease
Xu, L.-Z., Li, B.-Q., & Jia, J.-P. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1242-2 · Cited by 42
De Strooper, B., & Karran, E. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00057-w · Cited by 36
Self-citationMullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.027 · Cited by 32
Versatile nanomaterials for Alzheimer’s disease: Pathogenesis inspired disease-modifying therapy
Xi, Y., Chen, Y., Jin, Y., Han, G., Song, M., Song, T., Shi, Y., Tao, L., Huang, Z., Zhou, J., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.034 · Cited by 27
Genes, pathways and risk prediction in Alzheimer’s disease
Hardy, J., & Escott-Price, V. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz163 · Cited by 27
Self-citationGeerts, H., Hofmann‐Apitius, M., Anastasio, T. J., & Initiative, B. H. M. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.08.011 · Cited by 20
Metadata
- Authors
- Karran, E., & Hardy, J.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2014-07-02
- Volume
- 76
- Issue
- 2
- Pages
- 185-205
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1585083630
- Cited by
- 275
- References
- 135
- FWCI
- 20.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.